

Drug Monograph

Drug Name: **Vuity™ (pilocarpine) ophthalmic drops**
 Drug Class: **Ophthalmic: Cholinergic Muscarinic Receptor Agonist**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Vuity is available in a 2.5 mL bottle containing a 1.25% pilocarpine solution.

Manufacturer: Distributed by: Allergan, an AbbVie Company, North Chicago, IL 60064.

Indications: Vuity is indicated for the treatment of presbyopia in adults.

Costs: \$73.49 per 2.5 mL bottle. Wholesale Acquisition Cost

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation:

<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input checked="" type="checkbox"/> Open Access	<input type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
<input checked="" type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD
 Date: December 30, 2021